Latest news with #EuropeanAcademyofAllergyandClinicalImmunology
Barnama
2 days ago
- Health
- Barnama
EAACI Launches Global Campaign To Combat Antibiotic Allergy Mislabelling
KUALA LUMPUR, Aug 18 (Bernama) -- The European Academy of Allergy and Clinical Immunology (EAACI) has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow, marking the start of a global initiative to address mislabelling and its link to antimicrobial resistance (AMR). In a statement, the association said inaccurate antibiotic allergy labels affect millions of patients worldwide, leading to avoidance of first-line treatments and increased reliance on second-line antibiotics, a practice that fuels AMR. EAACI is calling on stakeholders, including healthcare providers, policymakers and educators, to promote accurate diagnosis and responsible antibiotic use.
The Sun
17-07-2025
- Health
- The Sun
EAACI Congress 2025 highlights allergy and immunology breakthroughs
KUALA LUMPUR: The European Academy of Allergy and Clinical Immunology (EAACI) has declared its 2025 Congress a defining moment for the field, following the event's conclusion in Glasgow last month. With over 7,600 attendees, the congress emphasised scientific progress, equitable healthcare, and environmental sustainability. Held from June 13 to 16 at the Scottish Event Campus, the event carried the theme, 'Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future.' EAACI President Prof Maria Torres described it as a turning point, stating, 'We are entering an era where scientific innovation, equity in care, and environmental health must move forward together.' Prof André Moreira, EAACI Vice President Congresses, highlighted the collaborative spirit of the event, saying, 'The energy we witnessed in Glasgow is now translating into real-world initiatives and global partnerships.' The programme featured over 250 hours of sessions, covering key topics such as drug allergy, paediatric asthma, and hereditary angioedema. Notable discussions included a Presidential Symposium on antimicrobial resistance and a session on climate change's impact on insect allergy. Beyond academic sessions, the congress engaged Glasgow's community through public education at the Clinical Village and a charity walk supporting the Glasgow Children's Hospital Charity. Looking ahead, EAACI is preparing for its 2026 Congress in Istanbul, with plans for further scientific engagement through meetings and training courses. - Bernama
Barnama
17-07-2025
- Health
- Barnama
EAACI Congress 2025 Marks Turning Point In Allergy, Immunology
KUALA LUMPUR, July 17 (Bernama) -- The leadership of European Academy of Allergy and Clinical Immunology (EAACI) is reflecting on what they describe as a pivotal moment for the field, a month after the conclusion of EAACI Congress 2025 in Glasgow. The congress is being hailed as a turning point in allergy and immunology, making headlines not only for its scale but also for the bold, forward-thinking message delivered by its leadership. Over 7,600 delegates attended. Held from June 13 to 16 at Scottish Event Campus, the event embraced the theme, 'Breaking Boundaries in Allergy, Asthma, and Clinical Immunology: Integrating Planetary Health for a Sustainable Future', according to a statement. 'This year's Congress was a turning point. We are entering an era where scientific innovation, equity in care, and environmental health must move forward together,' said EAACI President, Prof Maria Torres. Meanwhile, EAACI Vice President Congresses, Prof André Moreira said: 'The spirit of collaboration we witnessed in Glasgow was extraordinary. This energy is now translating into real-world initiatives and global partnerships.' The programme featured over 250 hours of lectures, workshops, and symposia, covering groundbreaking advances in drug allergy, T2 inflammation, paediatric asthma, and hereditary angioedema. A Presidential Symposium on antimicrobial resistance adopted a One Health approach, while a standout session on climate change and insect allergy spotlighted the ecological challenges reshaping patient care. Beyond the conference halls, the congress activated the city of Glasgow through community engagement initiatives. The Clinical Village at the Glasgow Science Centre welcomed the public for interactive allergy education, and the Beat Allergy Walk & Run raised funds for the Glasgow Children's Hospital Charity, exemplifying EAACI's commitment to public health and outreach. EAACI 2025 also reinforced its priorities in mentorship, digital health innovation, and patient empowerment, signalling a holistic approach to the future of allergy and clinical immunology.
Yahoo
17-06-2025
- Business
- Yahoo
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while maintaining a price target of $30.00. This whopping 237% upside from the current price followed the company's positive three-year data for its hereditary angioedema (HAE) treatment presentation at the European Academy of Allergy and Clinical Immunology meeting. What emerged from the findings was truly impressive. The Phase 1 trial data demonstrated that a single dose of lonvoguran ziclumeran (lonvo-z, or NTLA-2002) resulted in a 98% mean reduction in monthly HAE attack rates in all 10 patients evaluated. A lab scientist peering into a microscope focused on gene editing technology. The treatment maintained effectiveness throughout the three years, with sustained effects noted across the study. These results are in sync with the nature of gene editing, which is designed to produce lasting changes to the genome. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-headquartered clinical-stage gene editing company. The giant develops curative genome editing treatments. In collaboration with AvenCell Therapeutics, Inc., the company aims to create innovative therapies for a range of diseases. While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
16-06-2025
- Health
- Business Wire
KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of new data at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom that underscores the critical role of effective on-demand (OD) treatment for HAE attacks among patients receiving long-term prophylaxis (LTP). Sebetralstat for Treatment of HAE Attacks in Patients Receiving Berotralstat, Lanadelumab, or C1 Inhibitor for Long-term Prophylaxis: Interim Analysis from KONFIDENT-S waspresented by Marc A. Riedl, MD, Professor of Medicine and Clinical Director of the US Hereditary Angioedema Association Center at the University of California, San Diego. The KONFIDENT-S interim analysis, involving 35 participants receiving berotralstat, lanadelumab, or C1 inhibitor (C1-INH), treated 382 attacks with sebetralstat Median time to treatment was 6 minutes overall, ranging from 1 minute (C1-INH) to 20 minutes (berotralstat) One-third of attacks were still mild at time of sebetralstat use Median time to beginning of symptom relief was 1.3 hours "Even with advancements in HAE long-term prophylactic treatments, attacks still occur, highlighting the critical need for easily administered, fast-acting, effective on-demand options," said Dr. Riedl. "These data from KONFIDENT-S show the promise of sebetralstat as an effective oral on-demand option that can complement all major long-term prophylaxis treatments, including those acting through plasma kallikrein inhibition, like lanadelumab and berotralstat.' Adherence to Long-Term Prophylaxis for Hereditary Angioedema and the Impact on On-demand Treatment Claims in the US was presented by Daniel Soteres, MD, MPH, Asthma and Allergy Associates and Research Center, Colorado. Less than half (44%) of HAE patients using LTP were adherent based on refill data over 12 months No reduction in OD claims was observed in non-adherent patients (18 pre- and post-LTP; p =0.769) Over 12 months, greater than 20% discontinued their LTP, while 17% switched LTP "The real-world data suggest that despite the effectiveness of long-term prophylactic therapies in clinical trials, maintaining adherence may be a significant hurdle for many HAE patients," said Dr. Soteres. "Refill gaps correlated with a greater number of on-demand treatment claims, indicating that patients may be experiencing more frequent attacks than expected. This underscores the importance of actively discussing LTP adherence with patients and having a reliable, efficacious on-demand treatment to manage breakthrough attacks.' 'These data reinforce what we hear from patients and clinicians on an ongoing basis; long-term prophylaxis plays an essential role in HAE management, but it's not the full story,' said Paul Audhya, M.D., MBA, Chief Medical Officer of KalVista. 'Attacks still occur, and adherence remains a real-world challenge. Sebetralstat is designed to meet this need: a rapid, reliable oral treatment that empowers patients to act the moment symptoms begin, regardless of their background therapy.' Links to all presentations can be found on the KalVista website under Publications. About Sebetralstat Sebetralstat is an investigational, novel oral plasma kallikrein inhibitor for the treatment of hereditary angioedema (HAE). We have filed multiple regulatory applications seeking approval of sebetralstat as the first oral, on-demand treatment for HAE in individuals aged 12 and older, with ongoing studies exploring its use in children aged 2 to 11. If approved, sebetralstat has the potential to become the foundational therapy for HAE management worldwide. About Hereditary Angioedema Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. All currently approved on-demand treatment options require either intravenous or subcutaneous administration. About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the U.S. FDA. In addition, we have completed Marketing Authorization Applications for sebetralstat to the European Medicines Agency and multiple other global regulatory authorities. For more information about KalVista, please visit or follow us on social media at @KalVista and LinkedIn. Forward-Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
